Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CpG-Activated Whole Cell Vaccine and Autologous Immunotransplant for Mantle Cell Lymphoma
NCT00490529Phase 2Completed
- Start
- Aug 2009
- Primary completion
- Dec 2017
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CpG-MCL in mantle cell lymphoma (MCL). Primary endpoint: Freedom From Molecular Residual Disease Post-autologous Stem Cell Transplant at 12 months. Started Aug 2009; status: completed.
02
Drugs
CpG-MCL
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00490529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490529.